Abbott Sews Up Puncture Seal Deal As Perclose Stock Falls On Recall Rumors
This article was originally published in The Gray Sheet
Executive Summary
Abbott's July 8 acquisition of Perclose in a stock swap valued at about $680 mil. portends the firm's long-term strategy to expand its interventional cardiology presence at a tempered pace.
You may also be interested in...
Abbott Integrates Vascular Closure Technology With $65 Mil. Purchase Of IVS
Abbott Labs' acquisition of Sunnyvale, Calif.-based Integrated Vascular Systems builds on the larger firm's promise to pursue high-growth medical technology areas following an August spin-off its Hospital Products unit
Abbott Integrates Vascular Closure Technology With $65 Mil. Purchase Of IVS
Abbott Labs' acquisition of Sunnyvale, Calif.-based Integrated Vascular Systems builds on the larger firm's promise to pursue high-growth medical technology areas following an August spin-off its Hospital Products unit
Reimbursement, Sales Critical For IPOs As Markets Reopen To Device Firms
"Reimbursement clarity" is essential for device firms in gaining investor confidence in the public equity market, Jeffrey Hoffman, health technology investment banker with U.S. Bancorp Piper Jaffray, emphasized at the recent Frost & Sullivan 5th Annual Medical Devices and Diagnostics Industry Conference in San Francisco.